Feb 24, 2022 / 09:00AM GMT
Martin Ãmark - Xbrane Biopharma AB - CEO
Thank you and welcome, everybody, to this call for presentation of our year-end report for 2021. My name is Martin, I am the CEO of Xbrane. And I will just start by giving a brief overview of what we've been up to during 2021, from an operational perspective. Anette, our CFO, who's with me here, will go through financial details of fourth quarter. And then I will end the call with talking a little bit about our focus for 2022.
I'll just start here with an overview of our portfolio of biosimilar candidates. As you all know, our leading biosimilar candidate is Xlucane with reference to present this in a registration phase with EMA and the BLA, soon to be submitted to FDA and partnered with STADA and Bausch + Lomb.
Second product is we call Xcimzane, biosimilar candidate to Cimzia, which we recently partnered up with Biogen. And then we have a portfolio of three biosimilar candidates to Opdivo, Keytruda, and Darzalex, respectively, that are more early-stage development. And we are targeting to be able to bring these products to market by the time of
Q4 2021 Xbrane Biopharma AB Earnings Call Transcript
Feb 24, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers